Seven months after a surprise rejection from regulators in the US, Sanofi has presented new late-stage data on its rare blood disorder drug sutimlimab which will provide the basis for a submission in Europe and a resubmission Stateside in the coming months.
The French giant has presented data at the European Hematology Association meeting on sutimlimab from a second Phase III study...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?